Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Sci

Retrieve available abstracts of 117 articles:
HTML format
Text format



Single Articles


    November 2018
  1. PENG A, Qiu X, Zhang L, Zhu X, et al
    Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review.
    J Neurol Sci. 2018;396:202-205.
    PubMed     Text format    


  2. FRITZ NE, Kloos AD, Kegelmeyer DA, Kaur P, et al
    Supplementary motor area connectivity and dual-task walking variability in multiple sclerosis.
    J Neurol Sci. 2018;396:159-164.
    PubMed     Text format     Abstract available


  3. MEJIA M, Rodriguez-Leyva I, Cortes-Enriquez F, Chi-Ahumada E, et al
    Low levels of alpha-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study.
    J Neurol Sci. 2018;396:87-93.
    PubMed     Text format     Abstract available


    October 2018
  4. ZILIOTTO N, Zivadinov R, Jakimovski D, Baroni M, et al
    Plasma levels of soluble NCAM in multiple sclerosis.
    J Neurol Sci. 2018;396:36-41.
    PubMed     Text format     Abstract available


    September 2018
  5. HEALY BC, Glanz BI, Zurawski JD, Mazzola M, et al
    Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
    J Neurol Sci. 2018;394:127-131.
    PubMed     Text format     Abstract available


  6. POLACHINI CRN, Spanevello RM, Schetinger MRC, Morsch VM, et al
    Cholinergic and purinergic systems: A key to multiple sclerosis?
    J Neurol Sci. 2018;392:8-21.
    PubMed     Text format     Abstract available


    August 2018
  7. JAKIMOVSKI D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, et al
    Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.
    J Neurol Sci. 2018;393:128-134.
    PubMed     Text format     Abstract available


  8. POKRYSZKO-DRAGAN A, Banaszek A, Nowakowska-Kotas M, Jezowska-Jurczyk K, et al
    Diffusion tensor imaging findings in the multiple sclerosis patients and their relationships to various aspects of disability.
    J Neurol Sci. 2018;391:127-133.
    PubMed     Text format     Abstract available


    July 2018
  9. CRISTIANO E, Rojas JI, Abad P, Adoni T, et al
    Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America.
    J Neurol Sci. 2018;393:4-13.
    PubMed     Text format     Abstract available


  10. VOLLMER B, Honce JM, Sillau S, Corboy JR, et al
    The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.
    J Neurol Sci. 2018;390:89-93.
    PubMed     Text format     Abstract available


  11. ZHANG Y, Wang L, Jia H, Liao M, et al
    Genetic variants regulate NR1H3 expression and contribute to multiple sclerosis risk.
    J Neurol Sci. 2018;390:162-165.
    PubMed     Text format     Abstract available


    June 2018
  12. KHALID F, Healy BC, Dupuy SL, Chu R, et al
    Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.
    J Neurol Sci. 2018;392:94-99.
    PubMed     Text format     Abstract available


  13. GROMISCH ES, Portnoy JG, Foley FW
    Response to screening ability of cognitive function by two measures in patients with multiple sclerosis.
    J Neurol Sci. 2018 Jun 14. pii: S0022-510X(18)30259.
    PubMed     Text format    


  14. KAWADA T
    Screening ability of cognitive function by two measures in patients with multiple sclerosis.
    J Neurol Sci. 2018 Jun 13. pii: S0022-510X(18)30258.
    PubMed     Text format    


    May 2018
  15. KADRNOZKOVA L, Vaneckova M, Sobisek L, Benova B, et al
    Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.
    J Neurol Sci. 2018;388:87-93.
    PubMed     Text format     Abstract available


  16. GROMISCH ES, Portnoy JG, Foley FW
    Comparison of the abbreviated minimal assessment of cognitive function in multiple sclerosis (aMACFIMS) and the brief international cognitive assessment for multiple sclerosis (BICAMS).
    J Neurol Sci. 2018;388:70-75.
    PubMed     Text format     Abstract available


  17. ZIVADINOV R, Bergsland N, Hagemeier J, Carl E, et al
    Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.
    J Neurol Sci. 2018;388:175-181.
    PubMed     Text format     Abstract available


  18. KANTOR D, Johnson K, Vieira MC, Signorovitch J, et al
    Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2018;388:168-174.
    PubMed     Text format     Abstract available


  19. FABIS-PEDRINI MJ, James I, Seewann A, Yau WY, et al
    Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort.
    J Neurol Sci. 2018;388:12-18.
    PubMed     Text format     Abstract available


  20. MANCA R, Sharrack B, Paling D, Wilkinson ID, et al
    Brain connectivity and cognitive processing speed in multiple sclerosis: A systematic review.
    J Neurol Sci. 2018;388:115-127.
    PubMed     Text format     Abstract available


    April 2018
  21. DALGAS U, Langeskov-Christensen M, Skjerbaek A, Jensen E, et al
    Is the impact of fatigue related to walking capacity and perceived ability in persons with multiple sclerosis? A multicenter study.
    J Neurol Sci. 2018;387:179-186.
    PubMed     Text format     Abstract available


  22. VYVER MV, Beelen R, De Keyser J, Nagels G, et al
    Plasma citrulline levels are increased in patients with multiple sclerosis.
    J Neurol Sci. 2018;387:174-178.
    PubMed     Text format     Abstract available


  23. ZIVADINOV R, Bergsland N, Hagemeier J, Tavazzi E, et al
    Effect of switching from glatiramer acetate 20mg/daily to glatiramer acetate 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    J Neurol Sci. 2018;387:152-156.
    PubMed     Text format     Abstract available


  24. AKAISHI T, Takahashi T, Nakashima I
    Oligoclonal bands and periventricular lesions in multiple sclerosis will not increase blood-brain barrier permeability.
    J Neurol Sci. 2018;387:129-133.
    PubMed     Text format     Abstract available


  25. GRIST JT, Riemer F, McLean MA, Matys T, et al
    Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from (23)Na-MRI.
    J Neurol Sci. 2018;387:111-114.
    PubMed     Text format     Abstract available


    March 2018
  26. FENU G, Lorefice L, Arru M, Sechi V, et al
    Cognition in multiple sclerosis: Between cognitive reserve and brain volume.
    J Neurol Sci. 2018;386:19-22.
    PubMed     Text format     Abstract available


    February 2018
  27. MORROW SA, Rosehart H, Sener A, Welk B, et al
    Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis.
    J Neurol Sci. 2018;385:39-44.
    PubMed     Text format     Abstract available


  28. BUNAI T, Terada T, Kono S, Yokokura M, et al
    Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study.
    J Neurol Sci. 2018;385:30-33.
    PubMed     Text format     Abstract available


  29. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2018;385:217-224.
    PubMed     Text format     Abstract available


  30. PODBIELSKA M, O'Keeffe J, Hogan EL
    Autoimmunity in multiple sclerosis: role of sphingolipids, invariant NKT cells and other immune elements in control of inflammation and neurodegeneration.
    J Neurol Sci. 2018;385:198-214.
    PubMed     Text format     Abstract available


  31. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Corrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224].
    J Neurol Sci. 2018 Feb 12. pii: S0022-510X(18)30061.
    PubMed     Text format    


    January 2018
  32. BERTSCH-GOUT M, Loeb R, Finch AK, Javed A, et al
    High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status.
    J Neurol Sci. 2018;384:61-66.
    PubMed     Text format     Abstract available


    December 2017
  33. DALLA-COSTA G, Radaelli M, Maida S, Sangalli F, et al
    Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice.
    J Neurol Sci. 2017;383:166-168.
    PubMed     Text format     Abstract available


  34. LINGENBERG A, Laidet M, Armand S, Herrmann FR, et al
    Gait stability in patients treated by fingolimod: A longitudinal pilot study on 9 patients with multiple sclerosis.
    J Neurol Sci. 2017;383:105-107.
    PubMed     Text format    


    November 2017
  35. PEREZ-MARTIN MY, Gonzalez-Platas M, Jimenez-Sosa A, Plata-Bello J, et al
    Can fibrinolytic system components explain cognitive impairment in multiple sclerosis?
    J Neurol Sci. 2017;382:66-72.
    PubMed     Text format     Abstract available


  36. PLANCHE V, Moisset X, Morello R, Dumont E, et al
    Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    J Neurol Sci. 2017;382:148-154.
    PubMed     Text format     Abstract available


  37. LANGESKOV-CHRISTENSEN D, Feys P, Baert I, Riemenschneider M, et al
    Performed and perceived walking ability in relation to the Expanded Disability Status Scale in persons with multiple sclerosis.
    J Neurol Sci. 2017;382:131-136.
    PubMed     Text format     Abstract available


    October 2017
  38. YOUSUF F, Dupuy SL, Tauhid S, Chu R, et al
    A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    J Neurol Sci. 2017 Oct 16. pii: S0022-510X(17)34384.
    PubMed     Text format     Abstract available


  39. MILLER P, Soundy A
    The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis.
    J Neurol Sci. 2017;381:41-54.
    PubMed     Text format     Abstract available


  40. KARAMI M, Mehrabi F, Allameh A, Pahlevan Kakhki M, et al
    Klotho gene expression decreases in peripheral blood mononuclear cells (PBMCs) of patients with relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2017;381:305-307.
    PubMed     Text format     Abstract available


  41. FERREIRA D, Castro P, Videira G, Filipe JP, et al
    Cerebral autoregulation is preserved in multiple sclerosis patients.
    J Neurol Sci. 2017;381:298-304.
    PubMed     Text format     Abstract available


  42. CALVI A, De Riz M, Lecchi E, Pietroboni A, et al
    Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    J Neurol Sci. 2017;381:296-297.
    PubMed     Text format    


  43. OLIVEIRA SR, Simao ANC, Alfieri DF, Flauzino T, et al
    Vitamin D deficiency is associated with disability and disease progression in multiple sclerosis patients independently of oxidative and nitrosative stress.
    J Neurol Sci. 2017;381:213-219.
    PubMed     Text format     Abstract available


  44. CORREALE J
    Follow-on products for treatment of multiple sclerosis in Latin America: An update.
    J Neurol Sci. 2017;381:153-159.
    PubMed     Text format     Abstract available


  45. BEIER M, Gromisch ES, Hughes AJ, Alschuler KN, et al
    Proposed cut scores for tests of the Brief International Cognitive Assessment of Multiple Sclerosis (BICAMS).
    J Neurol Sci. 2017;381:110-116.
    PubMed     Text format     Abstract available


  46. MCGEE JC, Minagar A
    Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view.
    J Neurol Sci. 2017 Oct 13. pii: S0022-510X(17)34383.
    PubMed     Text format    


    September 2017
  47. YAMOUT BI, Said M, Hannoun S, Zeineddine M, et al
    Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
    J Neurol Sci. 2017;380:79-81.
    PubMed     Text format     Abstract available


  48. YANG TT, Wang L, Deng XY, Yu G, et al
    Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;380:256-261.
    PubMed     Text format     Abstract available


  49. GREEKE EE, Chua AS, Healy BC, Rintell DJ, et al
    Depression and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;380:236-241.
    PubMed     Text format     Abstract available


  50. IWANOWSKI P, Losy J, Kramer L, Wojcicka M, et al
    CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    J Neurol Sci. 2017;380:22-26.
    PubMed     Text format     Abstract available


  51. LAIDET M, Herrmann FR, Armand S, Assal F, et al
    Does fear of falling predict gait variability in multiple sclerosis?
    J Neurol Sci. 2017;380:212-214.
    PubMed     Text format     Abstract available


  52. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237].
    J Neurol Sci. 2017;380:19.
    PubMed     Text format    


  53. PICELLI A, Vallies G, Chemello E, Castellazzi P, et al
    Is spasticity always the same? An observational study comparing the features of spastic equinus foot in patients with chronic stroke and multiple sclerosis.
    J Neurol Sci. 2017;380:132-136.
    PubMed     Text format     Abstract available


    August 2017
  54. SANTORO M, Mirabella M, De Fino C, Bianco A, et al
    Sativex(R) effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.
    J Neurol Sci. 2017;379:298-303.
    PubMed     Text format     Abstract available


  55. GAETANI L, Fanelli F, Riccucci I, Eusebi P, et al
    High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline.
    J Neurol Sci. 2017;379:236-240.
    PubMed     Text format     Abstract available


  56. KEUNE PM, Young WR, Paraskevopoulos IT, Hansen S, et al
    Measuring standing balance in multiple sclerosis: Further progress towards an automatic and reliable method in clinical practice.
    J Neurol Sci. 2017;379:157-162.
    PubMed     Text format     Abstract available


  57. MORSALJAHAN Z, Rafiei A, Valadan R, Abedini M, et al
    Association between interleukin-32 polymorphism and multiple sclerosis.
    J Neurol Sci. 2017;379:144-150.
    PubMed     Text format     Abstract available


    July 2017
  58. FARROKHI M, Masoudifar A, Peykanpour F
    Interleukin 17 and 10 in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017;378:63.
    PubMed     Text format    


  59. ROLF L, Muris AH, Bol Y, Damoiseaux J, et al
    Vitamin D3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression.
    J Neurol Sci. 2017;378:30-35.
    PubMed     Text format     Abstract available


  60. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    J Neurol Sci. 2017;378:233-237.
    PubMed     Text format     Abstract available


  61. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Concerning the article "Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients".
    J Neurol Sci. 2017;378:152.
    PubMed     Text format    


    June 2017
  62. AGLIARDI C, Guerini FR, Zanzottera M, Rovaris M, et al
    Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians.
    J Neurol Sci. 2017;377:31-34.
    PubMed     Text format     Abstract available


  63. CALABRO RS, Russo M, Naro A, De Luca R, et al
    Robotic gait training in multiple sclerosis rehabilitation: Can virtual reality make the difference? Findings from a randomized controlled trial.
    J Neurol Sci. 2017;377:25-30.
    PubMed     Text format     Abstract available


  64. TRENTINI A, Castellazzi M, Romani A, Squerzanti M, et al
    Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients.
    J Neurol Sci. 2017;377:133-136.
    PubMed     Text format     Abstract available


  65. SMOLDERS J, Rolf L, Damoiseaux J, Hupperts R, et al
    On the ethics of not supplementing low 25-hydroxyvitamin D levels in a controlled study in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30383.
    PubMed     Text format    


  66. SHUKLA L, Solanki C, Kulkarni Y, Vadlamani N, et al
    Vitamin D supplementation; effects on depressive symptoms in multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30384.
    PubMed     Text format    


    May 2017
  67. JORGENSEN M, Dalgas U, Wens I, Hvid LG, et al
    Muscle strength and power in persons with multiple sclerosis - A systematic review and meta-analysis.
    J Neurol Sci. 2017;376:225-241.
    PubMed     Text format     Abstract available


  68. HEESEN C, Kleiter I, Meuth SG, Kramer J, et al
    Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
    J Neurol Sci. 2017;376:181-190.
    PubMed     Text format     Abstract available


  69. BSTEH G, Monz E, Zamarian L, Hagspiel S, et al
    Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice - The PeRiCoMS-Study I.
    J Neurol Sci. 2017;376:71-75.
    PubMed     Text format     Abstract available


  70. WEINSTOCK-GUTTMAN B, Nair KV, Glajch JL, Ganguly TC, et al
    Two decades of glatiramer acetate: From initial discovery to the current development of generics.
    J Neurol Sci. 2017;376:255-259.
    PubMed     Text format     Abstract available


    April 2017
  71. BOURNE T, Waltz M, Casper TC, Kavak K, et al
    Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.
    J Neurol Sci. 2017;375:371-375.
    PubMed     Text format     Abstract available


  72. LYSANDROPOULOS AP, Mavroudakis N, Pandolfo M, El Hafsi K, et al
    HLA genotype as a marker of multiple sclerosis prognosis: A pilot study.
    J Neurol Sci. 2017;375:348-354.
    PubMed     Text format     Abstract available


  73. NOORI-ZADEH A, Mesbah-Namin SA, Saboor-Yaraghi AA
    Epigenetic and gene expression alterations of FOXP3 in the T cells of EAE mouse model of multiple sclerosis.
    J Neurol Sci. 2017;375:203-208.
    PubMed     Text format     Abstract available


  74. RUBEGNI A, Battisti C, Tessa A, Cerase A, et al
    SPG2 mimicking multiple sclerosis in a family identified using next generation sequencing.
    J Neurol Sci. 2017;375:198-202.
    PubMed     Text format     Abstract available


  75. HARTL C, Obermeier V, Gerdes LA, Brugel M, et al
    Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients.
    J Neurol Sci. 2017;375:160-164.
    PubMed     Text format     Abstract available


  76. REEN GK, Silber E, Langdon DW
    Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review.
    J Neurol Sci. 2017;375:107-122.
    PubMed     Text format     Abstract available


    February 2017
  77. ZHOU Y, Fang L, Peng L, Qiu W, et al
    TLR9 and its signaling pathway in multiple sclerosis.
    J Neurol Sci. 2017;373:95-99.
    PubMed     Text format     Abstract available


  78. WUNDES A, Bowen JD, Kraft GH, Maravilla KR, et al
    Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    J Neurol Sci. 2017;373:339-341.
    PubMed     Text format     Abstract available


  79. LANGESKOV-CHRISTENSEN M, Bisson EJ, Finlayson ML, Dalgas U, et al
    Potential pathophysiological pathways that can explain the positive effects of exercise on fatigue in multiple sclerosis: A scoping review.
    J Neurol Sci. 2017;373:307-320.
    PubMed     Text format     Abstract available


  80. FERREIRA KP, Oliveira SR, Kallaur AP, Kaimen-Maciel DR, et al
    Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:236-241.
    PubMed     Text format     Abstract available


  81. KAWADA T
    Poor sleep and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:143.
    PubMed     Text format    


  82. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Response to the letter to the Editor for the manuscript "Sleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort study" by Tomoyuki Kawada.
    J Neurol Sci. 2017;373:142.
    PubMed     Text format    


  83. ZAHOOR I, Haq E, Asimi R
    Multiple sclerosis in Kashmir: Where we stand.
    J Neurol Sci. 2017;373:129-133.
    PubMed     Text format     Abstract available


  84. TOGHI M, Taheri M, Arsang-Jang S, Ohadi M, et al
    SOCS gene family expression profile in the blood of multiple sclerosis patients.
    J Neurol Sci. 2017 Feb 9. pii: S0022-510X(17)30111.
    PubMed     Text format     Abstract available


    January 2017
  85. ALGAHTANI H, Marzouk Y, Algahtani R, Salman S, et al
    Autosomal Recessive Cerebellar Ataxia type 1 mimicking multiple sclerosis: A report of two siblings with a novel mutation in SYNE1 gene in a Saudi family.
    J Neurol Sci. 2017;372:97-100.
    PubMed     Text format     Abstract available


  86. MOTL RW, Sandroff BM, Pilutti LA, Klaren RE, et al
    Physical activity, sedentary behavior, and aerobic capacity in persons with multiple sclerosis.
    J Neurol Sci. 2017;372:342-346.
    PubMed     Text format     Abstract available


  87. BOESCHOTEN RE, Braamse AM, Beekman AT, Cuijpers P, et al
    Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;372:331-341.
    PubMed     Text format     Abstract available


  88. CAMEROTA F, Celletti C, Di Sipio E, De Fino C, et al
    Focal muscle vibration, an effective rehabilitative approach in severe gait impairment due to multiple sclerosis.
    J Neurol Sci. 2017;372:33-39.
    PubMed     Text format     Abstract available


  89. SABATINO JJ JR, Newsome SD
    Stiff person syndrome masquerading as multiple sclerosis.
    J Neurol Sci. 2017;372:297-299.
    PubMed     Text format     Abstract available


  90. CRNOSIJA L, Krbot Skoric M, Gabelic T, Adamec I, et al
    Vestibular evoked myogenic potentials and MRI in early multiple sclerosis: Validation of the VEMP score.
    J Neurol Sci. 2017;372:28-32.
    PubMed     Text format     Abstract available


  91. KISIC-TEPAVCEVIC D, Pekmezovic T, Trajkovic G, Stojsavljevic N, et al
    Corrigendum to "Sexual dysfunction in multiple sclerosis: A 6-year follow-up study" [J. Neurol. Sci. 358 (2015) 317-323].
    J Neurol Sci. 2017;372:201.
    PubMed     Text format    


  92. CHALAH MA, Riachi N, Ahdab R, Mhalla A, et al
    Effects of left DLPFC versus right PPC tDCS on multiple sclerosis fatigue.
    J Neurol Sci. 2017;372:131-137.
    PubMed     Text format     Abstract available


  93. TAO C, Simpson S Jr, Taylor BV, van der Mei I, et al
    Association between human herpesvirus & human endogenous retrovirus and MS onset & progression.
    J Neurol Sci. 2017;372:239-249.
    PubMed     Text format     Abstract available


  94. BEH SC, Kildebeck E, Narayan R, Desena A, et al
    High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.
    J Neurol Sci. 2017;372:187-195.
    PubMed     Text format     Abstract available


  95. TANIKAWA M, Nakahara J, Hata J, Suzuki S, et al
    q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with fingolimod: A preliminary study.
    J Neurol Sci. 2017 Jan 5. pii: S0022-510X(17)30010.
    PubMed     Text format     Abstract available


  96. KIRA JI
    q-space Myelin Map imaging: A new imaging technique for treatment evaluation in multiple sclerosis.
    J Neurol Sci. 2017 Jan 4. pii: S0022-510X(17)30009.
    PubMed     Text format    


    December 2016
  97. KOUDRIAVTSEVA T
    Body mass index and interferon-beta efficacy (and safety) in multiple sclerosis.
    J Neurol Sci. 2016;371:79-80.
    PubMed     Text format    


    November 2016
  98. HERNANDEZ ME, Holtzer R, Chaparro G, Jean K, et al
    Brain activation changes during locomotion in middle-aged to older adults with multiple sclerosis.
    J Neurol Sci. 2016;370:277-283.
    PubMed     Text format     Abstract available


  99. SQUINTANI G, Donato F, Turri M, Deotto L, et al
    Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    J Neurol Sci. 2016;370:263-268.
    PubMed     Text format     Abstract available


  100. O'GORMAN CM, Broadley SA
    Smoking increases the risk of progression in multiple sclerosis: A cohort study in Queensland, Australia.
    J Neurol Sci. 2016;370:219-223.
    PubMed     Text format     Abstract available


  101. DE GIGLIO L, Upadhyay N, De Luca F, Prosperini L, et al
    Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis.
    J Neurol Sci. 2016;370:211-213.
    PubMed     Text format    


  102. GAINDH D, Kavak KS, Teter B, Vaughn CB, et al
    Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
    J Neurol Sci. 2016;370:13-17.
    PubMed     Text format     Abstract available


  103. GASPERINI C, Hupperts R, Lycke J, Short C, et al
    Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
    J Neurol Sci. 2016;370:123-131.
    PubMed     Text format     Abstract available


  104. HUHN K, Lammer R, Zimmermann H, Lammer A, et al
    Retinal imaging and axonal degeneration in later onset multiple sclerosis.
    J Neurol Sci. 2016;370:1-6.
    PubMed     Text format     Abstract available


    October 2016
  105. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study.
    J Neurol Sci. 2016 Oct 27. pii: S0022-510X(16)30684.
    PubMed     Text format     Abstract available


  106. EFTEKHARIAN MM, Noroozi R, Sayad A, Sarrafzadeh S, et al
    RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis.
    J Neurol Sci. 2016;369:259-62.
    PubMed     Text format     Abstract available


  107. BERNARDINI LR, Zecca C, Clerici VT, Gobbi C, et al
    Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis.
    J Neurol Sci. 2016;369:139-40.
    PubMed     Text format    


  108. YANG F, Estrada EF, Sanchez MC
    Vibration training improves disability status in multiple sclerosis: A pretest-posttest pilot study.
    J Neurol Sci. 2016;369:96-101.
    PubMed     Text format     Abstract available


  109. MANDEL JJ, Goethe EA, Patel AJ, Heck K, et al
    Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis.
    J Neurol Sci. 2016;369:51-2.
    PubMed     Text format    


  110. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2016;369:36-8.
    PubMed     Text format     Abstract available


    September 2016
  111. BRAMBILLA L, Rossi Sebastiano D, Aquino D, Torri Clerici V, et al
    Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    J Neurol Sci. 2016;368:402-7.
    PubMed     Text format     Abstract available


  112. MESSMER UCCELLI M, Traversa S, Ponzio M
    A survey study comparing young adults with MS and healthy controls on self-esteem, self-efficacy, mood and quality of life.
    J Neurol Sci. 2016;368:369-73.
    PubMed     Text format     Abstract available


  113. SACCA F, Pane C, Carotenuto A, Massarelli M, et al
    The use of medical-grade cannabis in patients non-responders to Nabiximols.
    J Neurol Sci. 2016;368:349-51.
    PubMed     Text format    


    June 2016
  114. KUUSISTO H, Vahvelainen T, Hamalainen P, Luukkaala T, et al
    Asymptomatic subjects differ less from their twin siblings with MS than from healthy controls in cognitive functioning. A Finnish Twin Cohort study.
    J Neurol Sci. 2016;365:50-3.
    PubMed     Text format     Abstract available


    April 2016
  115. TREMLETT H, Fadrosh DW, Faruqi AA, Hart J, et al
    Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
    J Neurol Sci. 2016;363:153-7.
    PubMed     Text format     Abstract available


    March 2016
  116. HUDA S, Cavey A, Izat A, Mattison P, et al
    Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.
    J Neurol Sci. 2016;362:66-8.
    PubMed     Text format     Abstract available


    January 2016
  117. MOORE P, Methley A, Pollard C, Mutch K, et al
    Cognitive and psychiatric comorbidities in neuromyelitis optica.
    J Neurol Sci. 2016;360:4-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: